GreenLight Biosciences Debt to Equity

GreenLight Biosciences (GRNA) currently reports a debt-to-equity ratio of 3.53. That is above the sector sector average of 0.2. Use the charts on this page to explore GreenLight Biosciences's debt-to-equity ratio history and peer comparisons.

GreenLight Biosciences's debt-to-equity ratio of 3.53 is higher than the its sector sector average of 0.2. That is roughly 1659.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The debt-to-equity ratio is a valuation multiple that relates GreenLight Biosciences's market price to a fundamental measure such as earnings, sales, or book value. At 3.53, GRNA can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current debt-to-equity ratio of 3.53, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 0.2. From there, open related valuation or income-statement pages for GreenLight Biosciences, and consider following GRNA for alerts when major investors trade the stock.